Immunotherapy for the treatment of prostate cancer

  title={Immunotherapy for the treatment of prostate cancer},
  author={Giuseppe Di Lorenzo and Carlo Buonerba and Philip W. Kantoff},
  journal={Nature Reviews Clinical Oncology},
Failure of immune surveillance has a prominent role in tumorigenesis. Cancerous cells can evade T-cell responses to tumor-associated antigens by multiple mechanisms. Active immunotherapy aims to stimulate the immune response against cancer cells. Unlike normal prostate tissue, prostate cancer is not ignored by the immune system, as shown by the presence of tumor infiltrating lymphocytes. This characteristic renders prostate cancer particularly suitable for immunotherapy. The existence of well… 
Potentiating prostate cancer immunotherapy with oncolytic viruses
Oncolytic viruses, originally used for their preferential cancer-killing activity, are now being recognized for their ability to overturn cancer-associated immune evasion and promote otherwise absent antitumour immunity.
Cell-mediated immunotherapy for hepatocellular carcinoma
Among the various strategies for cancer immunotherapy, cell-mediated immunotherapy holds considerable promise to overcome anergy and systemic immune suppression and this brief review will focus on cell- mediated immunotherapy for HCC.
Immunotherapy for Prostate Cancer Enters Its Golden Age
As immunotherapy for prostate cancer enters its golden age, the challenge of the future will be to design rational combinations of immunotherapy agents with each other or with other standard prostate cancer treatments in an effort to improve patient outcomes further.
Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy
The identification of PSGR-derived peptide epitopes recognized by CD8+ T cells in an HLA-A2 dependent manner is described, which may be used as diagnostic markers as well as immune targets for development of anticancer vaccines.
Dendritic cell trafficking in tumor-bearing mice
This work aimed to study trafficking of DC in vivo via various routes of delivery, to optimize the effectiveness of DC-based therapy, and found subcutaneous injection of primed DC leads to highest preferential trafficking to the immunocompetent organs.
Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector
CD40 targeting significantly improved the therapeutic antitumor efficacy of Ad5-huPSMA encoding PSMA when combined with Ad 5-IFNγ in the RM-1-PSMA model, suggesting that a CD-targeted adenovirus delivering PSMA may be effective clinically for prostate cancer immunotherapy.
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
  • P. Corn
  • Biology, Medicine
    Cancer management and research
  • 2012
An improved understanding of the complex relationship between cancer epithelial cells and the organ-specific microenvironments with which they interact has created a powerful opportunity to develop novel therapies.
Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future?
Ipilimumab, a monoclonal antibody directed to an immunologic checkpoint molecule, showed a survival benefit in patients with advanced melanoma and appeared to correlate in some cases with the development of autoimmune events, signaling that the immune system is in overdrive against the cancer.
Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures.
The generation of new oncogene-specific prostate cancer cell lines that recapitulate human prostate cancer gene expression are a valuable new resource for testing targeted therapy, whereas the molecular signatures identified herein provides further value over current gene signature markers of prediction and outcome.


T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
  • M. Mercader, B. Bodner, E. Kwon
  • Medicine, Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 2001
The induction of T cell infiltration in prostate tissues treated with androgen ablation may have implications for the immunotherapeutic treatment of prostate cancer as well as other hormone-sensitive malignancies, including breast carcinoma.
Therapeutic vaccines for prostate cancer.
A review of recent advances and clinical trials in immunotherapy for prostate cancer along with current thoughts on immunologic and clinical monitoring of these trials highlights a promising future for the treatment of prostate cancer.
Prostate cancer as a model for tumour immunotherapy
  • C. Drake
  • Biology, Medicine
    Nature Reviews Immunology
  • 2010
Although this Review focuses on immunotherapy for prostate cancer, the principles discussed are applicable to many tumour types, and the approaches discussed are highlighted in that context.
Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide
In conclusion, immunization with PSA-peptide induced specific T cell immunity in one-half of the patients with locally advanced and hormone-sensitive, metastatic CaP.
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Results show that this combination immunotherapy can induce the expansion not only of activated effector CD8 T cells in vivo but also of T cells that are specific for known tumor-associated antigens from the endogenous immune repertoire.
Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer
Preclinical and early phase clinical studies using radiolabeled J591 have demonstrated efficacy in targeting tumor cells and decreasing levels of prostate‐specific antigen, and the dose‐limiting toxicity is reversible myelosuppression with little nonhematologic toxicity.
Phase I/II Trial of an Allogeneic Cellular Immunotherapy in Hormone-Naïve Prostate Cancer
This non-patient-specific prostate cancer immunotherapy has a favorable safety profile and is immunologically active and continued clinical investigation at higher doses and with longer boosting schedules is warranted.
Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer.
The autologous cell vaccine is safe and seems to induce a positive immune cellular response, and there seems to be some influence of the vaccine in PSA evolution after RRP.